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Background: pneumococcal conjugate vaccines (pCV) are being imple-
mented globally using a variety of different schedules. the optimal sched-
ule to maximize protection of vaccinated children against vaccine-type 
invasive pneumococcal disease (Vt-IpD) is not known.
Methods: to assess the relative benefit of various pCV dosing schedules, 
we conducted a systematic review of studies published in english from 
1994 to 2010 (supplemented post hoc with studies from 2011) on pCV 
effectiveness against Vt-IpD among children targeted to receive vaccine. 
Data on 2-dose and 3-dose primary series, both with and without a booster 
(“2+0,” “2+1,” “3+0” and “3+1”), were included. For observational studies 
using surveillance data or case counts, we calculated percentage reduction 
in Vt-IpD before and after pCV introduction.
Results: Of 4 randomized controlled trials and 31 observational studies 
reporting Vt-IpD among young children, none evaluated a 2+0 complete 
series, 7 (19%) evaluated 2+1, 4 (11%) 3+0 and 27 (75%) 3+1. most (86%) 
studies were from north America or europe. Only 1 study (observational) 
directly compared 2 schedules (3+0 vs. 3+1); results supported the use of 
a booster dose. In clinical trials, vaccine efficacy ranged from 65% to 71% 
with 3+0 and 83% to 94% with 3+1. Surveillance data and case counts 
demonstrate reductions in Vt-IpD of up to 100% with 2+1 (6 studies) or 
3+1 (17 studies) schedules and up to 90% with 3+0 (2 studies). Reductions 
were observed as early as 1 year after pCV introduction.
Conclusions: these data support the use of 2+1, 3+0 and 3+1 schedules, 
although most data of pCV impact on Vt-IpD among young children are 
from high-income countries using 3+1. Differences between schedules for 
impact on Vt-IpD are difficult to discern based on available data.
Key Words: pneumococcal conjugate vaccine, immunization schedule, 
invasive disease, systematic review
(Pediatr Infect Dis J 2014;33:S109–S118)
Streptococcus pneumoniae can cause a variety of clinical syn-dromes among both children and adults. When infection spreads 
to a normally sterile site, such as the brain or blood, the resulting 
syndrome, called invasive pneumococcal disease (IpD), is associ-
ated with significant morbidity and mortality. the burden of IpD 
falls disproportionately on young children, especially those in low-
income countries, and persons at high risk of infection because of 
underlying medical conditions such as HIV or sickle cell disease.1,2 
A limited number of pneumococcal serotypes cause the majority 
of IpD in both high- and low-risk groups; 7 of these serotypes are 
included in the 7-valent pneumococcal conjugate vaccine (pCV7), 
first licensed in February 2000.3 Within 6 years of pCV7 introduction 
in the united States, use of a 3-dose primary series with a booster 
in the second year of life (a “3+1” schedule) and a national catch-
up campaign among those under 5 years of age nearly eliminated 
vaccine-type IpD (Vt-IpD) among children targeted to receive the 
vaccine.4 more recently, licensed pCV formulations that include 10 
and 13 serotypes (pCV10 and pCV13, respectively) hold promise to 
further reduce the burden of pneumococcal disease.
Between 2000 and 2008, pCV7 was introduced into the 
national immunization programs of 26 countries, including 1 middle-
income country.5 As of December 2011, 77 countries offered pCV 
universally or had >50% coverage with the vaccine; 30 used a 3+1 
schedule and 47 used a reduced dose schedule of either 3 primary 
doses without a booster (3+0) or 2 primary doses with a booster (2+1) 
(Sources: Database maintained by WHO, supplemented with data 
from VImS [Vaccine Information management System of IVAC] 
and individual country reports or press releases). Although immuno-
genicity data support the use of reduced dose schedules for most 
 vaccine serotypes, whether reduced dose schedules can provide equiv-
alent protection against Vt-IpD to a 3+1 schedule when introduced 
into a national immunization program is unclear.6 the World Health 
Organization currently recommends that countries introduce pCV as 
part of the expanded programme on Immunisation schedule, yet spe-
cific guidance on the relative effectiveness of different pCV dosing 
schedules in various settings is lacking.7 public health leaders newly 
considering pCV introduction, as well as those with established pro-
grams, face challenging decisions regarding the most appropriate dos-
ing schedule for their populations, including the benefits of a 3-dose 
primary series compared with a 2-dose primary series, the benefits of 
a booster dose and whether a 3-dose series should be administered on 
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into the relative benefits of different dosing schedules by presenting 
findings from a systematic review of the available literature on pCV 
dosing effects on Vt-IpD among young children.
MATERIALS AND METHODS
Literature Search
this analysis is part of a larger project describing the impact 
of pCV dosing schedules on IpD, immunogenicity, nasopharyn-
geal carriage, pneumonia and indirect effects. Details on the litera-
ture search terms and methods used in this systematic review are 
described elsewhere (see methods Appendix8). In brief, a systematic 
literature review was performed to collect all available english lan-
guage data published from January 1994 to September 2010 (sup-
plemented post hoc with studies from 2011) on the effect of various 
pCV vaccination schedules among immunized children on immu-
nogenicity,  nasopharyngeal colonization, IpD, pneumonia and on 
indirect effects among unvaccinated populations. Articles published 
in 14 databases, from ad hoc unpublished sources and abstracts 
from meetings of the International Symposium on pneumococci and 
pneumococcal Disease (1998–2010) and the Interscience Confer-
ence on Antimicrobial Agents and Chemotherapeutics (1994–2010), 
were searched. We included all randomized controlled trials (RCts), 
nonrandomized trials, surveillance database analyses and observa-
tional studies of any pCV schedule on 1 or more outcomes of inter-
est. Studies were included for abstraction if 23-valent pneumococcal 
polysaccharide vaccine (ppV23) was used as a booster dose, but 
not as a primary dose. titles and abstracts were reviewed twice and 
those with relevant content on 1 of 5 outcomes (immunogenicity, 
carriage, invasive disease, pneumonia and indirect effects) under-
went full review using a standardized data collection instrument. We 
did not search non-english language literature because of the low 
likelihood they would have relevant data for this project. Details on 
the search methods are provided in the methods Appendix.8
Data Abstraction
Citations recovered through the literature search went through 
several stages of independent review to determine their eligibility, as 
described elsewhere.8 Citations meeting inclusion criteria were cat-
egorized on an outcome specific basis into “study families,” where 
each family included abstracts or publications generated from a 
single protocol, population, surveillance system or other data col-
lection system relevant to that outcome. Investigators identified pri-
mary data from the individual studies making up each study family 
for inclusion in the analysis. the primary data were selected as the 
most current and complete data available for that study family. In 
some cases, these data were drawn from more than 1 publication 
within a family. We also defined “study arms” as a group of children 
distinguished by immunization schedule or pCV product.
We abstracted core information on the following: number 
of children in a “study arm”; pCV manufacturer, valency and con-
jugate protein; coadministered vaccines; country; age at each dose 
and date of study and publication. Additional data for the IpD out-
come included rates of vaccine serotype IpD (per 100,000 popu-
lation), absolute case counts of Vt-IpD and reported percentage 
reduction in Vt-IpD after pCV introduction. Data on both Vt-IpD 
and Vt pneumococcal bacteremia were considered duplicative, in 
which case only Vt-IpD was included. We included both Vt-men-
ingitis and Vt-IpD within a single study family to allow characteri-
zation of the meningitis outcome independently of Vt-IpD.
Inclusion and Exclusion Criteria
We included all data published from RCts, nonrandomized 
trials, case-control studies, indirect cohort studies, surveillance data-
base analyses (population-based data) and case series (sentinel site 
data) using any pCV schedule if the citation or abstract reported data 
on Vt pneumococcal meningitis, Vt pneumococcal bacteremia or 
all Vt-IpD. to describe the direct impact of the vaccine among young 
children, we only included studies that reported data on children tar-
geted to receive vaccine; for surveillance analyses and case series, 
this meant limiting studies to those that reported impact of vaccine 
among children ≤2 years of age. For controlled trials, case-control 
studies and indirect cohort studies, data on children ≤5 years of age 
were also included as long as they were eligible to receive vaccine. 
We excluded studies that reported pneumococcal bacteremia only in 
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only among older age groups; these data are included in the articles 
on pneumonia and indirect effects, respectively, found in this supple-
ment.9,10 We also excluded review articles, those that only provided 
data for single serotypes and those that only reported data from either 
before or after pCV introduction but not from both periods.
Pneumococcal Vaccine Dosing Schedules
We defined a primary series as either 2 or 3 doses received 
before 7 months of age. A booster dose was defined as a dose of pCV 
or ppV23 received after 9 months of age and after the completion of 
a primary series. A complete series was defined as the primary series 
alone for settings where no booster was planned, or the primary series 
plus the booster dose for settings where this was part of the planned 
schedule; specifically, these include a 2-dose primary series with or 
without a booster of pCV or ppV23 (2+1, 2+0) or a 3-dose primary 
series with or without a booster of pCV or ppV23 (3+1, 3+0).
Data Analysis
the studies identified in this systematic review represent 
heterogeneous designs. even when clinical methods were similar 
TABLE 1. Descriptive Characteristics of Studies Reporting the Impact of PCV Dosing Schedules on IPD Among 
Young Children by Type of Study Design
Surveillance/Trend and Case 
Series Studies*
Case-Control and Indirect 
Cohort Studies Clinical Trials All Studies
(n = 25) (n = 6) (n = 4) (n = 35)
Date of publication
  1994–2002 0 (0%) 0 (0%) 1 (25%) 1 (2.9%)
  2003–2006 3 (12.0%) 2 (33.3%) 3 (75%) 8 (22.9%)
  2007–2010 22 (88.0%) 4 (66.7%) 0 (0%) 26 (74.2%)
Complete dosing series†
  2 + 0 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  2 + 1 6 (23.1%) 1 (16.7%) 0 (0%) 7 (19.4%)
  3 + 0 2 (7.7%) 0 (0%) 2 (50%) 4 (11.1%)
  3 + 1 or 3+PPV23 17 (76.9%) 5 (83.3%) 2 (50%) 27 (75.0%)
UN region‡
  Africa 0 (0%) 0 (0%) 2 (50%) 2 (5.7%)
  Asia 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  Oceania 3 (12.0%) 0 (0%) 0 (0%) 3 (8.6%)
  Europe 12 (48.0%) 2 (33.3%) 0 (0%) 14 (35.0%)
  Latin America and 
Caribbean
0 (0%) 0 (0%) 0 (0%) 0 (0%)
  North American 10 (40.0%) 4 (66.7%) 2 (50%) 16 (47.7%)
  Other region 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PCV product†
  PCV7 (Wyeth) 25 (100%) 6 (100%) 2 (50%) 33 (94.3%)
  PCV9 0 (0%) 0 (0%) 2 (50%) 2 (5.6%)
  PCV11 0 (0%) 0 (0%) 0 (0%) 0 (0%)
  PPV23 3 (12.0%) 0 (0%) 0 (0%) 3 (8.3%)
Outcome†
  VT-IPD 23 (92.0%) 6 (100%) 4 (100%) 33 (94.3%)
  VT-meningitis 3 (12.0%) 0 (0%) 0 (0%) 3 (8.6%)
  VT-bacteremia 2 (8.0%) 0 (0%) 0 (0%) 2 (5.7%)
*One VT-IPD study is comprised of 2 independent reports published in 2001 and 2006 (conducted in the US population using the same surveillance system). The later publica-
tion date is used.
†One study from Australia reported data using both a 3 + 0 and 3+PPV23 schedule.
‡United Nations “Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings” from http://unstats.un.org/unsd/
methods/m49/m49regin.htm.
2 + 0, 2 doses without booster; 2 + 1, 2 doses plus booster; 3 + 0, 3 doses without booster; 3 + 1, 3 doses plus booster.
TABLE 2. Randomized Clinical Trials Evaluating Efficacy of PCV Dosing Schedules Against VT-IPD Among  
Young Children
Country (Citation) Schedule Schedule and Product Total Sample Size Population
VE
(95% CI)
The Gambia (Cutts et al.)13 3 + 0 11, 15 and 24 weeks (PCV9, Wyeth) 17,437 General 71% (46–86)
South Africa (Klugman et al.)12 3 + 0 6, 10 and 14 weeks (PCV9, Wyeth) 39,836 HIV infected 65% (24–86)
HIV uninfected 83% (39–97)
United States (Black et al.)11 3 + 1 2, 4, 6 and 12–15 months (PCV7, Wyeth) 37,868 General 94% (80–99)
United States (O’Brien et al.)14 3 + 1 2, 4, 6 and 12–15 months (PCV7, Wyeth) 8,292 Native American 82.6% (21.4–96.1)
Finland (Palmu et al.)15 3 + 1
2 + 1
≥6 weeks and 2 doses at ≥4 weeks intervals,  
  booster at ≥11 months
≥6 weeks and 2 doses at ≥8 weeks interval,  
  booster at ≥11 months (PCV10, GSK)
47,369 General 100% (83–100)
92% (58–100)
All studies were double-blind; VE estimates are intent-to-treat.
3+0, 3 doses without booster; 3 + 1, 3 doses plus booster
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between studies, the analyses presented were often very differ-
ent. We attempted to identify studies that would allow comparison 
between schedules either by (1) directly comparing pCV sched-
ules within the same study, (2) including schedule-specific data 
compared with no vaccine within the same study or (3) includ-
ing schedule-specific data that could be compared between stud-
ies using similar methodology (eg, among indirect cohort studies). 
Data were first summarized in descriptive analyses to provide an 
overview of the amount and variability of the data by schedule and 
study method.
For RCt, vaccine efficacy was used as the measure of 
impact. For surveillance database analyses and case series reporting 
Vt-IpD over a given period, we calculated percentage reduction by 
defining baseline incidence as the mean of all data points reported 
before pCV introduction. When annual data on postintroduction 
incidence were available, we calculated percentage reduction from 
baseline using the data point given for each year reported. If annual 
data were not available, we used the percentage reduction reported 
in the study for the specified period. In cases where only the aver-
age postintroduction incidence rate over a period was provided, 
we calculated percentage reduction from baseline to the reported 
rate and assigned it to the median year of the date range provided. 
When possible, incidence rates during the year of introduction were 
excluded from these calculations. to compare the impact of vac-
cine in early with late phases postintroduction, we grouped data 
into ≤3 years after pCV introduction and >3 years after introduc-
tion. When information on pCV dosing schedules within national 
immunization programs was not reported, we obtained it through 
data reported by World Health Organization (http://apps.who.int/
immunization_monitoring/en/globalsummary/countryprofilesel-
ect.cfm) or the Vaccine Information management System (http://
www.jhsph.edu/ivac/vims).
Statistical significance was defined as P < 0.05; SAS version 
9.2 (SAS Institute Inc., Cary, nC) was used for all analyses.
RESULTS
Of 12,980 citations reviewed, we identified 99 study fami-
lies that included data on pCV and pneumococcal meningitis, bac-
teremia or all-IpD (Fig. 1). Of these, 35 study families (from 36 
reports) included data on young children receiving pCV, 33 (94%) 
reported data on only Vt-IpD, 2 (6%) reported on Vt-meningitis 
and Vt-IpD, 1 (3%) reported on Vt-bacteremia and Vt-meningitis 
and 1 (3%) reported only on Vt-bacteremia (Appendix). the types 
of studies reporting these data included 4 clinical RCts and 31 
observational studies.
most studies (n = 26; 74%) were published after 2007 and 
most were conducted in north America and europe (n = 30; 86%), 
although studies from Africa (n = 2) and Oceania (n = 3) were also 
represented (table 1). A 3+1 or 3+ppV23 schedule (n = 27; 75%) 
was more commonly evaluated than either 2+1 (n = 7; 19.4%) or 
3+0 (n = 4; 11.1%). no studies evaluated routine use of a 2+0 
schedule, although 5 (13.9%) observational studies looked at the 
effectiveness of a 2-dose primary series (ie, an incomplete series) 
in the setting of countries routinely using 2+1 or 3+1. three studies, 
all of which were conducted in Australia, used ppV23 as a booster 
dose. All but 2 studies evaluated pCV7; these 2 evaluated a 9-valent 
vaccine (pCV9). none of the studies evaluated pCV10 or pCV13.
Randomized Controlled Trials
We identified 4 double-blind RCts in 3 different coun-
tries; the studies evaluated vaccine efficacy against Vt-IpD among 
young children for either a 3+0 or 3+1 schedule compared with 
no pCV (table 2). no RCts with Vt-IpD outcomes directly com-
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the RCts—1 in the Gambia and the other in South Africa—used 
pCV9 in a 3+0 schedule setting and 2 used pCV7 in a 3+1 sched-
ule setting in the united States.11–14 In the Gambia, investigators 
compared 8189 vaccinated children to 8151 placebo controls and 
estimated efficacy against Vt-IpD to be 71% in their intent-to-treat 
(Itt) analysis.13 A similar Itt vaccine efficacy (83%) was demon-
strated in the South Africa trial involving over 39,000 children12; 
the vaccine was slightly less efficacious (65%) among children 
infected with HIV. the 2 studies conducted in the united States 
both reported high Itt vaccine efficacy, 1 (Ve 94%) was con-
ducted in the general uS population11 and the other (Ve 83%) was 
conducted among American Indian children, a population known to 
be at high risk for IpD.14
Case-Control and Indirect Cohort Studies
We identified 3 case-control studies and 3 indirect cohort 
studies that allowed for comparisons of different pCV schedules 
(table 3). these studies were conducted in 4 different countries 
routinely using either 2+1 or 3+1 schedules and estimated vaccine 
effectiveness of various pCV schedules compared with no pCV in 
either a 2+1 or a 3+1 vaccine setting.16–19 Despite varying study 
methods and settings, all studies used pCV7 and all showed sig-
nificant effectiveness against Vt-IpD among children targeted to 
receive vaccine. Across studies, point estimates of vaccine effec-
tiveness among partially vaccinated children who had received 2 
primary doses without a booster (2+0) ranged from 70% to 99%, 
2+1 ranged from 98% to 100%, 3+0 ranged from 77% to 98% and 
3+1 ranged from 81% to 100%. One case-control study, conducted 
in the united States, also directly analyzed the risk of Vt-IpD 
between schedules.17 In this analysis, a 3+1 schedule provided more 
protection against Vt-IpD than a 3+0 schedule (odds ratio = 0, 95% 
CI: 0–0.87); other direct comparisons were not significant but the 
number of children vaccinated on either 2+1 or 2+0 schedule was 
relatively small.
Observational Surveillance Studies or Case 
Series Studies
We identified 25 surveillance or case series study families 
(26 citations) conducted in 12 countries that described the impact 
of national pCV introduction on any Vt-IpD among young chil-
dren (table 4). Of these, 23 (92%) reported data on Vt-IpD of any 
syndrome, 2 (8%) on Vt-bacteremia without focus and 3 (12%) 
on Vt-meningitis. Although surveillance methods varied and each 
study only reported the impact of 1 particular pCV dosing sched-
ule, some general comparisons between schedules can be made 
across this group of reports. One similarity observed among nearly 
all studies was a significant impact of pCV introduction on Vt-IpD 
over time in populations routinely using 2+1, 3+0 and 3+1 sched-
ules; no data were available for a 2+0 schedule since no country 
routinely uses this schedule (Fig. 2). Reductions were also observed 
in the 4 studies conducted in indigenous populations: 2 conducted 
in Australia using 3+ppV23 and 2 conducted in the united States 
using a 3+1 schedule. percentage reduction in Vt-IpD ranged 
from 11% to 100% across studies, populations and time from vac-
cine introduction. A single study, conducted in Austria, reported 
an increase in Vt-IpD (50% increase) and a 4% decrease in Vt-
meningitis 2 years after pCV7 introduction although the number 
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pronounced reductions were seen >3 years compared with ≤3 years 
post pCV introduction (Fig. 3A, B). Studies reporting percentage 
change in both pneumococcal bacteremia and meningitis all took 
place in countries using a 3+1 schedule and all demonstrated reduc-
tions in Vt disease.
DISCUSSION
Our systematic review of the effect of different pCV dosing 
schedules on Vt-IpD among young children demonstrates the effec-
tiveness of pCV against Vt-IpD (of all syndromes), Vt-bacteremia 
and Vt-meningitis, across diverse study methods, populations and 
dosing schedules. the study designs captured by this approach are 
highly varied and complement recent summary measures (ie, meta-
analyses) which are limited to small numbers of studies of compara-
ble designs.6 In this way, our findings allow for a broader assessment 
of disease impact across different groups and time.
pCV7 was initially licensed with a 4-dose (3+1) sched-
ule46 and, not surprisingly, the vast majority of data on the impact 
of pCV on Vt-IpD among young children identified in this review 
originate from established programs using 3+1 schedules. these 
studies showed that a 3+1 schedule reduced Vt-IpD in a variety of 
settings and populations. using schedules with fewer than 4 doses 
is of increasing interest to policy makers introducing pCV who 
aim to optimally reduce disease in both vaccinated children and 
unvaccinated contacts, but who also are working with limited budg-
ets and crowded immunization schedules. no RCts or observational 
studies included in this review evaluated the effects of a 2+0 sched-
ule setting on Vt-IpD; however, both 2+1 and 3+0 schedule settings 
have demonstrated impact in a variety of epidemiological contexts. A 
3+0 pCV schedule has proven efficacy in 2 RCts conducted in low-
income settings12,13 and demonstrated impact against Vt-IpD among 
the general population of young children in Australia in 2 surveil-
lance studies.29,30 effectiveness of a 2+1 dosing schedule has been 
shown effective against Vt-IpD among partially vaccinated children 
in the united States where a 3+1 schedule is routinely used, and dis-
ease reductions were seen in several european countries and Quebec, 
Canada, where the national immunization program implemented a 
2+1 schedule with a catch-up campaign. Since completion of our 
literature search, a cluster-randomized, double-blind clinical trial was 
published that directly compared a 2+1 schedule to a 3+1 schedule 
using a 10-valent protein D pCV (pCV10) in Finland.15 In this study, 
vaccine effectiveness was 92% (95% CI: 58–100) with 2+1 doses 
and 100% (95% CI: 83–100%) with 3+1 doses, which is similar to 
estimates observed in clinical trials using 3+1 or 3+0 schedules in 
the united States, South Africa and the Gambia.11–14 Additional pop-
ulation-based data emerging from South Africa, a country with high 
HIV prevalence, has demonstrated a significant reduction in Vt-IpD 
among children <5 years old only 2 years following pCV introduc-
tion using a 2+1 schedule of pCV7 without catch-up.47
A B
Percentage change in VT-IPD, ≤3 years of PCV introduction
(n = 21 studies)
Percentage change in VT-IPD, >3 years after PCV introduction
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While differences in effectiveness may exist between 2+1 
and 3+0 schedules, we found no studies that directly compared IpD 
outcomes from these schedules to each other. the 2 case-control 
studies that evaluated the effectiveness of both 2+1 and 3+0 doses of 
pCV, compared with no vaccine, were conducted in countries using 
2+1 and 3+1 schedules with catch-up vaccination.17,20 Both studies 
showed significant and similar reductions in Vt-IpD among young 
children with either dosing schedule. Differences in impact between 
reduced dose schedules may be more significant in settings where 
pCV coverage is low and herd effects are not strong enough to allow 
for protection of unvaccinated individuals and high-risk groups. In 
addition, the sustainability of protection using reduced dose sched-
ules has not yet been fully documented. Here, we observe reduc-
tions in Vt-IpD using 3+1 and 3+ppV23 schedules up to 6 years 
after pCV introduction in the united States and Australia; however, 
further evaluation of 2+1 and 3+0 schedules is needed to determine 
whether they provide similar long-term protection.
One factor that may play a major role in differentiating between 
various reduced dose schedules is whether a booster dose confers 
added protection compared with a schedule without a booster dose. 
While this theory is supported by immunological and carriage data,48,49 
our search identified only 1 study that directly compared schedules to 
evaluate the benefit of a booster dose on Vt-IpD outcomes.17 this 
study found that a booster confers slightly higher protection against 
Vt-IpD; however, other case-control and indirect cohort studies that 
compared various pCV dosing schedules against no vaccine all found 
similar point estimates of effectiveness for schedules with or without 
a booster.16,18–21 All of these studies were conducted among the general 
population of young children. the 1 study that specifically evaluated 
the efficacy of pCV among HIV-infected children (an RCt in South 
Africa) suggested that a 3+0 schedule does not incur the same level 
of protection as in HIV-uninfected children.12 In the absence of data 
to determine whether a pCV booster dose may benefit such high-risk 
populations, lessons may be learned from other protein-conjugate vac-
cines used in low-income settings with high HIV prevalence. In recent 
years, data from South Africa have demonstrated a small increase in 
invasive Haemophilus influenzae type b (Hib) incidence using a 3+0 
schedule for Hib vaccine administered at 6, 10 and 14 weeks of age.50 
A similar but more marked phenomenon was observed in the united 
Kingdom using a 3+0 schedule for Hib at 2, 3 and 4 months of age.51 
In both countries, resurgence of Hib disease was controlled by the 
implementation of a booster dose. Although this phenomenon does 
not appear to be a common experience among other countries using 
Hib without a booster dose, there are few countries with sufficiently 
robust surveillance systems to identify such a resurgence should it 
occur. Whether lack of a pCV booster could result in a resurgence of 
Vt-IpD disease in areas with high HIV prevalence or other risk fac-
tors for disease has yet to be seen.
Another important consideration for policy makers contem-
plating reduced dose schedules is whether a difference may exist 
between a 2-dose and 3-dose primary series. minimal data exist on the 
benefits of a 2-dose primary series, and no studies directly compare 
2 doses to 3 doses. the studies that have reported on IpD impact of a 
2-dose primary series were all for partially vaccinated children in the 
setting of a national schedule using either 3 or 4 total doses.16,17,19,20,52 
Still, the ability for either 2 or 3 primary doses to provide some protec-
tion against Vt-IpD is supported in the literature through several key 
studies. three case-control and 3 indirect cohort studies in 4 different 
countries demonstrated a reduction in Vt-IpD among young children 
who received either 2 or 3 primary doses compared with no vac-
cine.16–20,52 Differences between the primary series were not discern-
ible in these studies. Although not included in this systematic review, 
a difference between primary series was suggested in a descriptive 
report using IpD surveillance data over a period of 27 months from 
the unites States. In this study, a greater number of invasive 6B break-
through cases were seen among children who had received a 2-dose 
primary series compared with 3 doses.53 this study was conducted in 
a country using a 3+1 schedule early after vaccine introduction and 
during a period of vaccine shortage, so therefore may not represent a 
true difference between a 2-dose primary series when compared with 
3-dose primary series, especially for an established program; never-
theless its findings are consistent with immunological and carriage 
data that suggest a 3-dose primary series may provide better protec-
tion than 2 primary doses for some vaccine serotypes, in particular 
serotype 6B.54–57 ultimately, however, the number and schedule of 
doses to include in a primary series may depend on the setting. using 
3 doses in the primary series may be preferable to 2 doses to optimize 
protection of infants in the first year of life or where attaining high 
coverage for routine vaccinations given late in the first year of life 
or in the second year (ie, given with measles vaccine) is challenging 
or uncertain. In mature pCV programs (where Vt carriage rates are 
low), the risk of disease experienced by children in the period before 
a booster dose may be sufficiently reduced such that the third priming 
dose is not a key element of a disease prevention strategy.
the studies captured by this review contribute to other sys-
tematic meta-analyses guiding policy decisions regarding pCV vac-
cine introduction.6,58,59 While these reviews also suggest that 3-dose 
schedules may provide significant protection against Vt-IpD in 
young children in high-income countries with established national 
immunization programs, the benefits of using different schedules 
may ultimately depend on the setting in which they are implemented. 
A 3-dose primary schedule may provide better protection in the first 
year of life when children are at highest risk of disease; however, a 
schedule with a booster dose (eg, 2+1) may provide enhanced long-
term protection, in particular for serotype 1.60 Our findings sup-
port decisions made by the pan American Health Organization and 
World Health Organization to recommend 3-dose schedules (either 
3+0 or 2+1) in countries with established programs, and the use of 
a 3-dose primary series in settings where vaccination coverage in 
the second year of life is low.61,62 more studies are needed to fully 
evaluate expanded serotype pCV products (pCV10 and pCV13) and 
to assess whether 2+1, 3+0 and 3+1 schedules provide equal protec-
tion against pneumococcal serotypes that particularly affect children 
in the second year of life, especially in low-income countries and 
countries with a high burden of HIV.
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APPENDIX. Citations Included in a Systematic Review of the Effects of Pneumococcal Vaccine Dosing Schedules on 
VT-IPD Among Young Children, by Study Type, Outcome, Dosing Schedule and Country
Code Citation(s) Outcome Age Group PCV Schedule Study Type Country
Surveillance studies and case series reports
 1 Aristegui et al.40 IPD <2 years 3+1 Surveillance Spain
 2 Benito-Fernandez et al. 44 Bacteremia 3–36 months 3+1 Case series Spain
 3 Black et al. 32
Black et al. 33
IPD <2 years 3+1 Surveillance United States
 4 Bjornson et al. 63 IPD 6–23 months 3+1 Surveillance Canada
 5 De Wals et al.25 IPD <2 years 2+1 Surveillance Canada
 6 Foster et al. 23 IPD <2 years 2+1 Surveillance United Kingdom
 7 Hanquet et al. 28 IPD, meningitis <2 years 2+1 Surveillance Belgium
 8 Harboe et al. 26 IPD <2 years 2+1 Surveillance Denmark
 9 Kaplan et al. 39 IPD <2 years 3+1 Case series United States
 10 Kellner et al. 34 IPD <2 years 3+1 Surveillance Canada
 11 Krause et al. 31 IPD <2 years 3+PPV23 Surveillance Australia
 12 Lehmann et al. 30 IPD <2 years 3+0, 3+PPV23 Surveillance Australia
 13 Lepoutre et al. 45 Meningitis, bacteremia <2 years 3+1 Surveillance France
 14 Miller et al. 27 IPD <2 years 2+1 Surveillance England/Wales
 15 Munoz et al. 38 IPD <2 years 3+1 Surveillance Spain
 16 Reingold et al. 200835 IPD <2 years 3+1 Surveillance United States
 17 Rendi-Wagner et al. 22 IPD, meningitis <2 years 3+1 Surveillance Austria
 18 Roche et al. 29 IPD <2 years 3+0, 3+PPV23 Surveillance Australia
 19 Rodenburg et al. 41 IPD <2 years 3+1 Surveillance Netherlands
 20 Ruckinger et al. 21 IPD <2 years 3+1 Surveillance Germany
 21 Singleton et al. 36 IPD <2 years 3+1 Surveillance United States
 22 Tyrrell et al. 37 IPD <2 years 3+1 Surveillance Canada
 23 Vestrheim et al. 24 IPD <2 years 2+1 Surveillance Norway
 24 Weatherholtz et al. 43 IPD <2 years 3+1 Surveillance United States
 25 Winters et al.42 IPD <2 years 3+1 Surveillance Canada
Case-control and indirect cohort studies
 26 Barricarte et al. 18 IPD <5 years 3+1 Case-control Spain
 27 Deceuninck et al. 20 IPD 2–59 months 2+1 Case-control Canada
 28 de Serres 19 IPD 3–59 months 3+1 Indirect cohort United States
 29 Mahon et al. 16 IPD <5 years 3+1 Indirect cohort United States
 30 Ruckinger et al. 52 IPD 3–59 months 3+1 Indirect cohort Germany
 31 Whitney et al. 17 IPD 3–36 months 3+1 Case-control United States
Clinical trials
 32 Black et al. 11 IPD 2–15 months 3+1 Clinical trial United States
 33 Cutts et al.13 IPD 6–51 weeks 3+0 Clinical trial The Gambia
 34 Klugman et al. 12 IPD 6–14 weeks 3+0 Clinical trial South Africa
 35 O’Brien et al. 14 IPD <2 years 3+1 Clinical trial United States
